These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 11076110

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
    Sun PP, Perianayagam MC, Jaber BL.
    J Ren Nutr; 2009 Sep; 19(5):432-8. PubMed ID: 19464926
    [Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage.
    Oka Y, Miyazaki M, Takatsu S, Kunitomo K, Uno F, Maruyama M, Matsuda H.
    Ther Apher Dial; 2007 Apr; 11(2):107-13. PubMed ID: 17381531
    [Abstract] [Full Text] [Related]

  • 67. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients.
    Collins AJ, St Peter WL, Dalleska FW, Ebben JP, Ma JZ.
    Clin Nephrol; 2000 Oct; 54(4):334-41. PubMed ID: 11076110
    [Abstract] [Full Text] [Related]

  • 68. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
    Nolan CR.
    Kidney Int Suppl; 2005 Jul; (96):S7-14. PubMed ID: 15954948
    [Abstract] [Full Text] [Related]

  • 69. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB, Shepler BM.
    Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
    [Abstract] [Full Text] [Related]

  • 70. [Phosphorus (P) chelant in dialysis: efficacy and cost. Peritoneal dialysis solutions].
    Montenegro J.
    Nefrologia; 2008 May; 28 Suppl 5():53-7. PubMed ID: 18847421
    [Abstract] [Full Text] [Related]

  • 71. [Sevelamer hydrochloride prevents ectopic calcification of blood vessels].
    Fukushima N, Nagano N.
    Clin Calcium; 2004 Jun; 14(6):116-22. PubMed ID: 15577065
    [Abstract] [Full Text] [Related]

  • 72. Renagel: a new and different phosphate binder.
    Ramsdell R.
    ANNA J; 1999 Jun; 26(3):346-7. PubMed ID: 10633608
    [Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB, Shepler BM.
    Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
    [Abstract] [Full Text] [Related]

  • 76. [Phosphorus (P) chelant in dialysis: efficacy and cost. Peritoneal dialysis solutions].
    Montenegro J.
    Nefrologia; 2008 May; 28 Suppl 5():53-7. PubMed ID: 18847421
    [Abstract] [Full Text] [Related]

  • 77. [Sevelamer hydrochloride prevents ectopic calcification of blood vessels].
    Fukushima N, Nagano N.
    Clin Calcium; 2004 Jun; 14(6):116-22. PubMed ID: 15577065
    [Abstract] [Full Text] [Related]

    Page: [Previous] [New Search]
    of 4.